Share on LinkedInShare on LinkedIn

ARTICLE · 02 JANUARY 2014

Conception And Reduction To Practice Of A DNA May Be Established Without The Full And Correct Nucleotide Sequence

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In "Sanofi-Aventis v. Pfizer Inc.", the Federal Circuit affirmed the Board’s award of priority of invention to Pfizer Inc.

United StatesIntellectual Property

In Sanofi-Aventis v. Pfizer Inc., No. 12-1345 (Fed. Cir. Nov. 5, 2013), the Federal Circuit affirmed the Board's award of priority of invention to Pfizer Inc. ("Pfizer") based on an interference count to an isolated polynucleotide cDNA encoding the human interleukin-13 receptor binding chain ("IL-13bc").

Both Pfizer and Sanofi-Aventis ("Sanofi") were conducting research on IL-13, a regulatory molecule called a cytokine, and both discovered and filed patent applications directed to the polynucleotide encoding the relevant binding chain, IL-13bc. During an interference proceeding, Sanofi was awarded the benefit of its December 6, 1995, priority date. Pfizer's earliest filing date was March 1, 1996, but Pfizer presented documentary and testimonial evidence that it had isolated and identified the desired cDNA before Sanofi's benefit date. Specifically, Pfizer presented evidence that its scientists had isolated full-length human IL-13bc from a human cDNA library

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from